Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

MaxCyte Inc (MXCT) Ord USD0.01 (DI)

Sell:840.00p Buy:850.00p Change: 5.00p (0.59%)
FTSE AIM 100:0.18%
Market closed |  Prices as at close on 19 April 2021 | Switch to live prices |
Change: 5.00p (0.59%)
Market closed |  Prices as at close on 19 April 2021 | Switch to live prices |
Change: 5.00p (0.59%)
Market closed |  Prices as at close on 19 April 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

MaxCyte, Inc. focuses on cell-based medicines. The Company provide high-performance cell-engineering platform to biopharmaceutical partners engaged in drug discovery and development, biomanufacturing and cell therapy, including gene editing and immuno-oncology. The Company’s platform allows for the engineering of nearly all cell types, including human primary cells, with any molecule, at any scale. The Company is developing CARMA, its platform in immuno-oncology, to rapidly manufacture chimeric antigen receptor (CAR) therapies for a broad range of cancer indications, including solid tumors where existing chimeric antigen receptor T cell (CAR-T) approaches face challenges. The Company's products include instruments, processing assemblies and insourcing services. The Company's instruments include systems, such as the MaxCyte STX, the MaxCyte VLX and the MaxCyte GT.

Contact details

22 Firstfield Rd Ste 110
United States
+1 (0301) 9441700

Important dates

Future events
Final results 20 April 2021 20/04/21
Past events
Trading Announcement 20 January 2021 20/01/21
Trading Announcement 23 December 2020 23/12/20
AGM 30 October 2020 30/10/20
Interim results 21 September 2020 21/09/20
Trading Announcement 15 July 2020 15/07/20
Final results 21 April 2020 21/04/20

General stock information

Market cap:
£802.03 million
Shares in issue:
94.91 million
Pharmaceuticals & Biotechnology
London Stock Exchange
Sterling pence

Key personnel

  • Douglas Doerfler
    President, Chief Executive Officer, Executive Director
  • Amanda Murphy
    Chief Financial Officer
  • Maher Masoud
    Executive Vice President, General Counsel
  • Thomas Ross
    Executive Vice President - Global Sales
  • Ronald Holtz
    Senior Vice President, Chief Accounting Officer, Executive Director
  • James Brady
    Vice President - Technical Applications and Customer Support
  • Steve Nardi
    Vice President, Manufacturing and Engineering Operations
  • Kathryn Wekselman
    Vice President - Regulatory
  • Sarah Meeks
    Vice President - Business Development
  • Shruti Abbato
    Executive Vice President - Business Development for CARMA Cellular Therapies

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by NBTrader.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.